To explain this, we next considered whether treatment with FDA-approved therapies at the time of Ag stimulus led to a shift in the phenotype of the resulting T cells such that they were more functionally able to control tumor seeding and growth and whether this could account for the more effective and durable antitumor immunity within those mice. The gene discussed is RENBP; the disease is neoplasm.